nach oben

Cardiovascular Toxicology

Erschienen in:

09.04.2021 | COVID-19 Zur Zeit gratis

Scientific Hypothesis for Treatment of COVID‐19′s Lung Lesions by Adjusting ACE/ACE2 Imbalance

verfasst von: F. Ferrara, A. Vitiello

Erschienen in: Cardiovascular Toxicology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

In March 2019 began the global pandemic COVID-19 caused by the new Coronavirus SARS-CoV-2. The first cases of SARS-CoV-2 infection occurred in November-19 in Wuhan, China. The preventive measures taken did not prevent the rapid spread of the virus to all countries around the world. To date, there are about 2.54 million deaths, effective vaccines are in clinical trials. SARS-CoV-2 uses the ACE-2 protein as an intracellular gateway. ACE-2 is a key component of the Renin Angiotensin (RAS) system, a key regulator of cardiovascular function. Considering the key role of ACE-2 in COVID-19 infection, both as an entry receptor and as a protective role, especially for the respiratory tract, and considering the variations of ACE-2 and ACE during the stages of viral infection, it is clear the important role that the pharmacological regulation of RAS and ACE-2 can assume. This biological knowledge suggests different pharmacological approaches to treat COVID-19 by modulating RAS, ACE-2 and the ACE/ACE2 balance that we describe in this article.

World health organization (WHO) https://www.who.int/emergencies/diseases/novel-coronavirus2019/situation-reports (Situation Reports Feb 2021).

Ferrara, F., Porta, R., D’Aiuto, V., & Vitiello, A. (2020). Remdesivir and COVID-19. Irish Journal of Medical Science, 17, 1–2. https://doi.org/10.1007/s11845-020-02401-5.CrossRef

Vitiello, A., & Ferrara, F. (2020). Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Irish Journal of Medical Science, 18, 1–2. https://doi.org/10.1007/s11845-020-02440-y.CrossRef

Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China. Intensive Care Med., 46(5), 846–848. https://doi.org/10.1007/s00134-020-05991-x.CrossRefPubMed

Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., & Zhou, Y. (2020). Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International Journal of Infectious Diseases, 94, 91–95. https://doi.org/10.1016/j.ijid.2020.03.017.CrossRefPubMedPubMedCentral

Ferrara, F., Granata, G., Pelliccia, C., La Porta, R., & Vitiello, A. (2020). The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? European Journal of Clinical Pharmacology, 76(11), 1615–1618. https://doi.org/10.1007/s00228-020-02947-4.CrossRefPubMed

Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., et al. (2020). Association of cardiac injury with mortality in hospitalized patients with covid-19 in Wuhan China. JAMA Cardiol., 5(7), 802–810. https://doi.org/10.1001/jamacardio.2020.0950.CrossRefPubMedPubMedCentral

Vitiello, A., Ferrara, F., Pelliccia, C., Granata, G., & La Porta, R. (2020). Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia. Italian Journal of Medicine., 14(2), 88–94. https://doi.org/10.4081/itjm.2020.1284.CrossRef

Ferrara, F. (2020). Antirheumatic in SARS-CoV-2: benefit or risk? Italian Journal of Medicine., 14(2), 114–115. https://doi.org/10.4081/itjm.2020.1290.CrossRef

10.

Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., et al. (2020). Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol., 5(7), 811–818. https://doi.org/10.1001/jamacardio.2020.1017.CrossRefPubMed

11.

Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181, 894–904.CrossRef

12.

Vitiello, V., & Ferrara, F. (2021). Colchicine and SARS-CoV-2 Management of the hyperinflammatory state. Respiratory Medicine, 178, 106322. https://doi.org/10.1016/j.rmed.2021.106322.CrossRefPubMedPubMedCentral

13.

Vitiello, A., La Porta, R., D’Aiuto, V., & Ferrara, F. (2021). Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Human Immunology. https://doi.org/10.1016/j.humimm.2021.01.007.CrossRefPubMedPubMedCentral

14.

Ferrara, F., & Vitiello, A. (2021). Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn-Schmiedeberg’s Archives of Pharmacology. https://doi.org/10.1007/s00210-021-02049-7.CrossRefPubMedPubMedCentral

15.

Vitiello, A., Ferrara, F., & Porta, R. (2021). Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Irish Journal of Medical Science, 12, 1–2. https://doi.org/10.1007/s11845-020-02482-2.CrossRef

16.

Yamamoto, S., Yancey, P. G., Zuo, Y., Ma, L. J., Kaseda, R., Fogo, A. B., Ichikawa, I., Linton, M. F., Fazio, S., & Kon, V. (2011). Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(12), 2856–2864. https://doi.org/10.1161/ATVBAHA.111.237198.CrossRefPubMedPubMedCentral

17.

Recinos, A., 3rd., LeJeune, W. S., Sun, H., Lee, C. Y., Tieu, B. C., Lu, M., Hou, T., Boldogh, I., Tilton, R. G., & Brasier, A. R. (2007). Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis, 194(1), 125–133. https://doi.org/10.1016/j.atherosclerosis.2006.10.013.CrossRefPubMed

18.

Pai, W. Y., Lo, W. Y., Hsu, T., Peng, C. T., & Wang, H. J. (2017). Angiotensin-(1–7) inhibits thrombin-induced endothelial phenotypic changes and reactive oxygen species production via NADPH oxidase 5 downregulation. Frontiers in Physiology, 8(8), 994. https://doi.org/10.3389/fphys.2017.00994.CrossRefPubMedPubMedCentral

19.

Magalhães, G. S., Rodrigues-Machado, M. G., & Motta-Santos, D. (2015). Angiotensin-(1–7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation. British Journal of Pharmacology., 172(9), 2330–2342. https://doi.org/10.1111/bph.13057.CrossRefPubMedPubMedCentral

20.

Vitiello, A., & Ferrara, F. (2020). Correlation between renin-angiotensin system and severe acute respiratory syndrome coronavirus 2 infection: What do we know? European Journal of Pharmacology, 883, 173373. https://doi.org/10.1016/j.ejphar.2020.173373.CrossRefPubMedPubMedCentral

21.

Vitiello, A., & Ferrara, F. (2021). Therapeutic Strategies for SARS-CoV-2 acting on ACE-2. European Journal of Pharmaceutical Sciences, 156, 105579. https://doi.org/10.1016/j.ejps.2020.105579.CrossRefPubMed

22.

Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine, 46(4), 586–590. https://doi.org/10.1007/s00134-020-05985-9.CrossRefPubMed

23.

Liu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., et al. (2020). Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci., 63(3), 364–374. https://doi.org/10.1007/s11427-020-1643-8.CrossRefPubMedPubMedCentral

24.

Zou, X., Chen, K., Zou, J., Han, P., Hao, J., & Han, Z. (2020). Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Frontiers in Medicine, 14(2), 185–192. https://doi.org/10.1007/s11684-020-0754-0.CrossRef

25.

Zhang J, Wu Y, Wang R, Lu K, Tu M,GuoH et al. (2020) Bioinformatic analysis reveals that the reproductive system is potentially at risk from SARS-CoV-2 doi: https://doi.org/10.20944/preprints202002.0307.v1

26.

Lukassen, S., Chua, R. L., Trefzer, T., Kahn, N. C., Schneider, M. A., Muley, T., et al. (2020). SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO Journal, 39(10), e105114. https://doi.org/10.15252/embj.20105114.CrossRef

27.

Su, H., Yang, M., Wan, C., Yi, L. X., Tang, F., Zhu, H. Y., Yi, F., Yang, H. C., Fogo, A. B., Nie, X., & Zhang, C. (2020). Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney International, 98(1), 219–227. https://doi.org/10.1016/j.kint.2020.04.003.CrossRefPubMedPubMedCentral

28.

Pan, X. W., Xu, D., Zhang, H., Zhou, W., Wang, L. H., & Cui, X. G. (2020). Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Medicine, 46(6), 1114–1116. https://doi.org/10.1007/s00134-020-06026-1.CrossRefPubMed

29.

Puelles, V. G., Lütgehetmann, M., Lindenmeyer, M. T., Sperhake, J. P., Wong, M. N., Allweiss, L., et al. (2020). Multiorgan and renal tropism of SARS-CoV-2. New England Journal of Medicine., 383, 590–592.CrossRef

30.

Douglas, G. C., O’Bryan, M. K., Hedger, M. P., Lee, D. K. L., Yarski, M. A., Smith, A. I., & Lew, R. A. (2004). The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis. Endocrinology, 145, 4703–4711.CrossRef

31.

Li, Y., Xu, Q., Ma, L., Wu, D., Gao, J., Chen, G., & Li, H. (2020). Systematic profiling of ACE2 expression in diverse physiological and pathological conditions for COVID-19/SARS-CoV-2. Journal of Cellular and Molecular Medicine., 24, 9478–9948.CrossRef

32.

Pinto, B. G. G., Oliveira, A. E. R., Singh, Y., Jimenez, L., Goncalves, A. N. A., Ogava, R. L. T., et al. (2020). ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19. The Journal of Infectious Diseases, 222, 556–563.CrossRef

33.

Higham, A., & Singh, D. (2020). Increased ACE2 Expression in Bronchial Epithelium of COPD Patients who are Overweight. Obesity (Silver Spring), 28(9), 1586–1589. https://doi.org/10.1002/oby.22907.CrossRef

34.

Vitiello, A., La Porta, R., & Ferrara, F. (2021). Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Medical Hypotheses, 147, 110486.CrossRef

35.

Vitiello, A., La Porta, R., D’Aiuto, V., & Ferrara, F. (2021). The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. Egypt Liver Journal., 11, 11. https://doi.org/10.1186/s43066-021-00082-y.CrossRef

36.

Ferrara, F., & Vitiello, A. (2020). Potential pharmacological approach in the regulation of ACE-2 and DPP-IV in diabetic COVID-19 patient. Italian Journal of Medicine. https://doi.org/10.4081/itjm.2020.1435.CrossRef

37.

Vitiello, A., Pelliccia, C., & Ferrara, F. (2021). Drugs acting on the renin-angiotensin system and SARS-CoV-2. Drug Discovery Today, S1359–6446(21), 00037–00044. https://doi.org/10.1016/j.drudis.2021.01.010.CrossRef

38.

Li, X., Rayford, H., & Uhal, B. D. (2003). Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. American Journal of Pathology, 163(6), 2523–2530. https://doi.org/10.1016/S0002-9440(10)63607-3.CrossRef

39.

Deng, J., Wang, D. X., Deng, W., Li, C. Y., & Tong, J. (2012). The effect of endogenous angiotensin II on alveolar fluid clearance in rats with acute lung injury. Canadian Respiratory Journal, 19(5), 311–318. https://doi.org/10.1155/2012/951025.CrossRefPubMedPubMedCentral

40.

Shen, L., Mo, H., Cai, L., Kong, T., Zheng, W., Ye, J., Qi, J., & Xiao, Z. (2009). Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock, 31(5), 500–506. https://doi.org/10.1097/SHK.0b013e318189017a.CrossRefPubMed

41.

Caldeira, D., Alarcão, J., Vaz-Carneiro, A., & Costa, J. (2012). Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ, 11(345), e4260. https://doi.org/10.1136/bmj.e4260.CrossRef

42.

Shrikrishna, D., Astin, R., Kemp, P. R., & Hopkinson, N. S. (2012). Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clinical Science (London, England), 123(8), 487–498. https://doi.org/10.1042/CS20120081.CrossRef

43.

Wang, R., Ramos, C., Joshi, I., Zagariya, A., Pardo, A., Selman, M., & Uhal, B. D. (1999). Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides. American Journal of Physiology, 277(6), L1158–L1164. https://doi.org/10.1152/ajplung.1999.277.6.L1158.CrossRef

44.

Wang, R., Zagariya, A., Ibarra-Sunga, O., Gidea, C., Ang, E., Deshmukh, S., Chaudhary, G., Baraboutis, J., Filippatos, G., & Uhal, B. D. (1999). Angiotensin II induces apoptosis in human and rat alveolar epithelial cells. American Journal of Physiology, 276(5), L885–L889. https://doi.org/10.1152/ajplung.1999.276.5.L885.CrossRef

45.

Papp, M., Li, X., Zhuang, J., Wang, R., & Uhal, B. D. (2002). Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. American Journal of Physiology. Lung Cellular and Molecular Physiology, 282(4), L713–L718. https://doi.org/10.1152/ajplung.00103.2001.CrossRefPubMed

46.

Wang, L., Wang, Y., Yang, T., Guo, Y., & Sun, T. (2015). Angiotensin-converting enzyme 2 attenuates bleomycin-induced lung fibrosis in mice. Cellular Physiology and Biochemistry, 36(2), 697–711. https://doi.org/10.1159/000430131.CrossRefPubMed

47.

Meng, Y., Yu, C. H., Li, W., Li, T., Luo, W., Huang, S., Wu, P. S., Cai, S. X., & Li, X. (2014). Angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-κB pathway. American Journal of Respiratory Cell and Molecular Biology, 50(4), 723–736. https://doi.org/10.1165/rcmb.2012-0451OC.CrossRefPubMed

48.

Xu, J., Huang, C., Fan, G., et al. (2020). Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Frontiers in Medicine, 14(5), 601–612. https://doi.org/10.1007/s11684-020-0800-y.CrossRef

49.

Khan, A., Benthin, C., Zeno, B., Albertson, T. E., Boyd, J., Christie, J. D., Hall, R., Poirier, G., Ronco, J. J., Tidswell, M., Hardes, K., Powley, W. M., Wright, T. J., Siederer, S. K., Fairman, D. A., Lipson, D. A., Bayliffe, A. I., & Lazaar, A. L. (2017). A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Critical Care, 21(1), 234. https://doi.org/10.1186/s13054-017-1823-x.CrossRefPubMedPubMedCentral

50.

Vitiello, A., & Ferrara, F. (2020). Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sciences, 1(262), 118510. https://doi.org/10.1016/j.lfs.2020.118510.CrossRef

51.

Vitiello, A., La Porta, R., & Ferrara, F. (2020). Sacubitril valsartan and SARS-CoV-2. BMJ Evid Based Med. https://doi.org/10.1136/bmjebm-2020-111497.CrossRefPubMed

52.

Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor molecular mechanisms and potential therapeutic target. Intensive Care Medicine, 46, 586–590.CrossRef

53.

Monteil, V., Kwon, H., Prado, P., et al. (2020). Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell, 181, 905–913.CrossRef

54.

Kuba, K., Imai, Y., Rao, S., et al. (2005). A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Medicine, 11, 875–879.CrossRef

55.

Haschke, M., Schuster, M., Poglitsch, M., et al. (2013). Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clinical Pharmacokinetics, 52, 783–792.CrossRef

56.

Khan, A., Benthin, C., & Zeno, B. (2017). A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Critical Care, 21, 234.CrossRef

57.

Minato, T., Nirasawa, S., Sato, T., Yamaguchi, T., Hoshizaki, M., Inagaki, T., et al. (2020). B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction. Nature Communications, 11(1), 1058. https://doi.org/10.1038/s41467-020-14867-z.CrossRefPubMedPubMedCentral

Titel: Scientific Hypothesis for Treatment of COVID‐19′s Lung Lesions by Adjusting ACE/ACE2 Imbalance
verfasst von: F. Ferrara
A. Vitiello
Publikationsdatum: 09.04.2021
Verlag: Springer US
Schlagwort: COVID-19
Erschienen in: Cardiovascular Toxicology / Ausgabe 6/2021
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-021-09649-y

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Springer Medizin

Scientific Hypothesis for Treatment of COVID‐19′s Lung Lesions by Adjusting ACE/ACE2 Imbalance

Abstract

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Proton Pump Inhibitor Exposure and Acute Myocardial Infarction Risk: A Nested Cohort Study

Cardiotoxic Effects of Micrurus surinamensis (Cuvier, 1817) Snake Venom

The Effect of Curcumin Nanoparticles on Cisplatin-Induced Cardiotoxicity in Male Wistar Albino Rats

Nrf1 Knock-Down in the Hypothalamic Paraventricular Nucleus Alleviates Hypertension Through Intervention of Superoxide Production-Removal Balance and Mitochondrial Function

Peripheral Administration of Nitroglycerin in Pulseless Ventricular Tachycardia due to Cocaine-Induced Coronary Vasospasm

Incessant Atrial Tachycardia Following Combination Chemotherapy with Cetuximab, Cisplatin and 5-Fluorouracil for Hypopharyngeal Cancer